For older adults with heart failure and reduced ejection fraction, digoxin is associated with a significant reduction in 30-day all-cause hospital admission, with no significant effect on mortality.
A centralized, patient preference-based program for depression care decreases symptoms in patients with post-acute coronary syndrome (ACS), according to a study published online March 7 in JAMA Internal Medicine.
For adults with previous myocardial infarction, high-dose oral vitamin and mineral supplementation is not associated with a reduction in cardiac events, according to a study presented at ACC.13.
Ranolazine reduces chest pain in patients with type 2 diabetes and angina, according to a study presented at ACC.13.
For older adults at risk of heart failure, B-type natriuretic peptide (NP)-guided screening and shared-care treatment is associated with a reduction in the prevalence of left ventricular dysfunction and heart failure.
For adults with diabetes, use of glucagon-like peptide 1 (GLP-1) analogs is associated with a reduced risk of heart failure hospitalization, all-cause hospitalization and all-cause mortality, according to a study by Henry Ford Hospital physicians.
For patients with systolic heart failure and mild-to-moderate anemia, treatment of anemia with darbepoetin alfa is not associated with improved clinical outcomes, a study in Sweden found.
In primary percutaneous coronary intervention (PCI), cangrelor correlates with reduced ischemic events, and prehospital fibrinolysis with timely angiography is effective for reperfusion in patients unable to undergo primary PCI within one hour after ST-segment elevation myocardial infarction (STEMI), according to two studies.
For patients undergoing nonemergency percutaneous coronary intervention (PCI), clinical outcomes at 30 days and one year are similar with and without on-site cardiac surgery services, according to a study published online March 11 in the New England Journal of Medicine.
Results from the ASTRONAUT trial show that adding aliskiren to standard therapy for chronic heart failure does not improve mortality or rehospitalization rates.
Results from the CORONARY trial show no significant difference at one year between patients with CAD who underwent on-pump vs. off-pump CABG.
Data from the PARTNER cohort A trial show transcatheter aortic valve replacement produces similar mortality rates at one year compared with the standard procedure.
Results from the PARTNER II trial show improvements in 30-day mortality and stroke rates in patients with aortic stenosis who are not surgical candidates who were treated using a newer version of the Sapien transcatheter aortic valve replacement system.
Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.
Study results presented at ACC.13 show that patients with unprotected left main coronary artery disease treated with double kissing crush stenting experienced fewer cases of restenosis and other major adverse events compared to patients who received culotte stenting.
Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.
Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.
Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study’s value for cardiologists over various recent heart failure trials.
Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.
Study results presented at ACC.13, the 62nd Annual Scientific Session & Expo of the American College of Cardiology, reveal that in selected STEMI patients, deferred stenting may reduce no-reflow and thrombotic events compared with immediate stenting.
Results of the ARMYDA-9 CAROTID trial indicate that loading with 600 mg clopidogrel and high-dose atorvastatin in carotid stent patients independently result in improved neurological outcomes.
Financial incentives can enhance sustained weight loss, according to a study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
Left gastric artery embolization seems safe and effective for weight loss in humans, according to a first-in-man study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
Stressful events, including hurricanes, earthquakes, and financial crises, correlate with increased incidence of acute myocardial infarction, according to three studies to be presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
News and updates about ACC.13, the 2013 Scientific Session of the American College of Cardiology.
Annual adult admissions for congenital heart disease are increasing and approaching that of pediatric admissions, according to a study published online March 7 in the Journal of the American Medical Association to coincide with presentation at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
Considerable seasonal variation has been observed in lipid profiles, according to a study to be presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
For patients with mild symptoms of heart failure implanted with cardiac resynchronization therapy with cardioverter defibrillator, weight loss is associated with increased risk of heart failure or death, according to a study to be presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
